Adjuvant Capital
Investor profile
Venture capital
Adjuvant Capital has backed 3 European tech companies across 5 funding rounds between 2022 and 2023, joining rounds totalling €181M. Most active in Healthtech. Data as of 4 Nov 2026.
Deals
5
distinct rounds
Companies
3
backed
Active span
2022–2023
2 yrs
Total round €
€181M
sum of rounds joined
Deals by year
distinct rounds / yearAdjuvant Capital — deals by year — interactive chart.
Data table
| Adjuvant Capital — deals by year | |
|---|---|
| 2022 | 3 |
| 2023 | 2 |
Top sectors
by dealsAdjuvant Capital — top sectors — interactive chart.
Data table
| Adjuvant Capital — top sectors | |
|---|---|
| Healthtech | 5 |
Stages
by dealsAdjuvant Capital — stages — interactive chart.
Data table
| Adjuvant Capital — stages | |
|---|---|
| Other | 3 |
| Series B | 1 |
| Series C | 1 |
Countries
by dealsAdjuvant Capital — countries — interactive chart.
Data table
| Adjuvant Capital — countries | |
|---|---|
| Denmark | 2 |
| Switzerland | 2 |
| Belgium | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Fresenius Medical Care Ventures2
- GF Group Holding2
- Industrifonden2
- LF Investment2
- Pureos Bioventures2
- Sanofi Ventures2
- Sunstone Life Science Ventures2
- Swisscanto Invest2
- Trill Impact Ventures2
- Verve Ventures2
- Vesalius Biocapital Partners2
- Wellington Partners2
- 3D1
- Christian Dumolin1
- EQT Life Sciences1
- Hubert Bonnet1
- Jean-Marc Heynderickx1
- Novo Holdings1
- Olivier van der Rest1
- OrbiMed1
- Pureos Ventures1
- Redalpine1
- Repair Impact Fund1
- Rodolphe de Spoelberch1
- Schroders Capital1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| MinervaX | Denmark | 2 | €76M |
| Memo Therapeutics | Switzerland | 2 | €61M |
| Univercells | Belgium | 1 | €44M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| MinervaX | Other | €54M | 2023-10 |
| Univercells | Other | €44M | 2022-10 |
| Memo Therapeutics | Series B | €35M | 2022-02 |
| Memo Therapeutics | Series C | €26M | 2023-11 |
| MinervaX | Other | €22M | 2022-12 |